ABCG2 and breast carcinoma: Luteolin is capable of inhibiting the expressions of stem-related transcription factors, the ATP-binding cassette transporter G2 (ABCG2), CD44, the activity of aldehyde dehydrogenase 1 (ALDH1), as well as the spherical-forming properties of breast cancer stem cells [36].